Here's Why You Should Add Inogen Stock to Your Portfolio Now

Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid second-quarter 2025 performance and a strong product portfolio, seems justified. However, issues like stiff competition and forex volatility are major downsides.The Zacks Rank #2 (Buy) company’s shares have lost 5.6% so far this year compared with the industry’s 11.5% decline. The S&P 500 has increased 14.4% during the same timeframe.The renowned provider of POCs has a market capitalization of $234.2 million. The company projects 37.5% earnings growth for 2025 and anticipates continued business improvements going forward. Inogen’s P/S ratio of 0.7X compared with the industry’s 2.7X makes its valuation attractive.Image Source: Zacks Investment ResearchLet us delve deeper.Huge Prospects in the POC Space: We remain confident in the advantages of POCs over traditional oxygen delivery methods. Inogen specializes in the development, manufacturing and marketing of innovative POCs designed to deliver long-term supplemental oxygen therapy for patients with chronic respiratory conditions.The company continued to demonstrate strong momentum in the POC market during the first half. Per management, the year-over-year uptick in the top line was primarily driven by higher demand and new customer gains across the domestic and international business-to-business channels. This performance reflects growing recognition of Inogen’s solutions, particularly due to their quality, ease of maintenance and extended service life. Per a report by Markets And Markets, the POCs market was valued at $15.05 billion in 2024 and is anticipated to reach $22.63 billion by 2029 at a CAGR of 8.5%.Product Portfolio: We are encouraged by Inogen’s expanding product portfolio and its potential to drive future growth. During the second quarter, the company launched a new stationary oxygen concentrator, Voxi 5, designed to enhance access to high-quality oxygen therapy for long-term care patients. INGN anticipates that the Rove 4 will make a meaningful contribution to revenue growth in 2025. Additionally, in December 2024, the company received FDA clearance to market Simeox in the United States, expanding its ability to meet the diverse needs of patients with chronic respiratory conditions.INGN finalized the strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. during the first quarter. The strategic collaboration is expected to broaden Inogen’s product portfolio by distributing select respiratory products in the United States and other key territories, enhance its innovation pipeline through R&D collaboration, and accelerate the brand’s entry into the Chinese market. This looks promising for the stock.Further strengthening its global presence, Inogen announced a strategic collaboration with Yuwell in January 2025. Yuwell is a leading global provider of home healthcare medical devices. The partnership is expected to expand Inogen’s product offerings through the U.S. and international distribution of select respiratory devices, support innovation via joint R&D initiatives and facilitate the company’s entry into the Chinese market.Strong Q2 Results: Inogen delivered solid second-quarter results in August, reflecting a 4% year-over-year increase in quarterly revenues. Second-quarter domestic and international business-to-business sales were up 19.3% and 17.7%, respectively, on a year-over-year basis. For 2025, Inogen now expects revenues in the range of $354-$357 million (reflecting approximately 6% growth at the midpoint of the range from the comparable 2024 revenues).RisksSeasonality Impact: The second quarter of 2025 reflected typical seasonal softness, particularly within the direct-to-consumer (DTC) channel. Management anticipates challenges in lead generation and heightened advertising headwinds over the upcoming quarters. Additionally, the DTC segment faced revenue pressure due to a leaner, more streamlined sales team — a factor that’s likely to further impact Inogen’s second-quarter performance.Forex Volatility: International markets contribute a significant portion to Inogen’s overall revenues. However, management expects overseas sales to remain volatile in the near term, largely due to the varying size and timing of distributor orders. Additionally, unfavorable foreign exchange trends are projected to weigh on revenue growth, as the strengthening U.S. dollar continues to pressure conversions from the euro and other currencies. In the second quarter of 2025, adverse currency movements negatively impacted international sales by 10 basis points.Estimate TrendInogen has been witnessing a positive estimate revision trend for 2025. In the past 60 days, the Zacks Consensus Estimate for its loss per share has narrowed 8.7% to 95 cents.The Zacks Consensus Estimate for 2025 revenues is pegged at $354 million, suggesting a 5.8% improvement from the year-ago reported number.Inogen, Inc Price Inogen, Inc price | Inogen, Inc QuoteOther Stocks to ConsiderSome other top-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. WST, AxoGen AXGN and Envista NVST.West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.AxoGen, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2025 EPS of 12 cents, which beat the Zacks Consensus Estimate by 100.0%. Revenues of $57 million outpaced the consensus mark by 7.1%.AxoGen has an estimated growth rate of 66.7% for 2026. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 33.3%.Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%. It currently carries a Zacks Rank #2.Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.50%.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report AxoGen, Inc. (AXGN): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Envista Holdings Corporation (NVST): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks